<DOC>
	<DOCNO>NCT00011921</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy peripheral stem cell transplant bone marrow transplant may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know whether high-dose chemotherapy plus peripheral stem cell bone marrow transplant effective chemotherapy alone treat small cell lung cancer . PURPOSE : This randomized phase III trial study well chemotherapy follow peripheral stem cell bone marrow transplant work compare chemotherapy alone treat patient limited-stage extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Bone Marrow Transplant Compared With Chemotherapy Alone Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient limit extensive stage small cell lung cancer treat sequential high-dose ifosfamide , carboplatin , etoposide phosphate follow autologous peripheral blood stem cell bone marrow transplantation versus standard ifosfamide , carboplatin , etoposide . - Compare progression-free survival , time treatment failure , response rate patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( limited disease v extensive disease v without liver metastasis ) , performance status ( 0 vs 1 ) , gender , LDH level ( normal v abnormal ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive induction therapy comprise epirubicin IV 4 hour day 1 paclitaxel IV 3 hour day 2 . Treatment repeat every 21 day total 2 course . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 3 continue 10 day course 2 peripheral blood stem cell ( PBSC ) collection complete . After completion induction chemotherapy , autologous PBSCs bone marrow collect . Within 28 day start second course induction chemotherapy , patient receive high-dose ifosfamide IV 17 hour , carboplatin IV 3 hour , etoposide phosphate IV 3 hour day 1-4 . At 48 hour completion high-dose chemotherapy , patient undergo autologous PBSC bone marrow transplantation receive G-CSF SC 14 day . Treatment repeat every 28 day 3 course . - Arm II : Patients receive ifosfamide IV continuously 24 hour , carboplatin IV 1 hour day 1 , etoposide IV 45 minute day 1 2 . Treatment repeat every 28 day 6 course . After completion high-dose standard chemotherapy , patient limit disease extensive disease complete remission receive thoracic radiotherapy daily day 1-5 6 week . All patient complete remission receive prophylactic cranial radiotherapy daily day 1-5 3 week . Quality life assess baseline , begin course 1 3 ( high-dose chemotherapy ) course 3 5 ( standard chemotherapy ) , 7 , 12 , 18 month . Patients follow monthly . PROJECTED ACCRUAL : A total 430 patient ( 215 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm small cell lung cancer Limited disease extensive disease 2 metastatic site No CNS metastasis PATIENT CHARACTERISTICS : Age : 65 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 OR Platelet count great 100,000/mm^3 OR Hemoglobin least 10.0 g/dL Hepatic : AST/ALT le 2.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Bilirubin less 2.5 time ULN Renal : Creatinine clearance least 60 mL/min No renal function would preclude chemotherapy Cardiovascular : No congestive heart failure LVEF least 50 % No cardiac function would preclude chemotherapy Other : No malignancy within past 3 year except basal cell skin cancer carcinoma situ cervix No psychiatric disorder disorder would preclude study participation Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>